92262-58-3
92262-58-3 結(jié)構(gòu)式
基本信息
N-丙戊?；拾滨０?BR>N-(2-氨基-2-氧代乙基)-2-丙基戊酰胺
VALROCEMIDE
Valrocemide, >98%
N-Valproylglycinamide
Valrocemide (TV1901,VGD))
N-(2-Amino-2-oxoethyl)-2-propylpentanamide
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-100379 | N-丙戊?；拾滨０?BR>Valrocemide | 92262-58-3 | 1 mg | 140元 |
| 2026/06/05 | HY-100379 | N-丙戊?；拾滨０?BR>Valrocemide | 92262-58-3 | 5mg | 280元 |
| 2026/06/05 | HY-100379 | N-丙戊?；拾滨０?BR>Valrocemide | 92262-58-3 | 10mM * 1mLin DMSO | 308元 |
常見問題列表
In mice, valrocemide affords complete protection against maximal electroshock-, pentylenetetrazole-, picrotoxin-, and bicuculline-induced seizures and 6-Hz “psychomotor” seizures with median effective dose (ED 50 ) values of 151, 132, 275, 248, and 237 mg/kg, respectively. Valrocemide is also effective in preventing sound-induced seizures in Frings audiogenic-seizure susceptible mice (ED 50 , 52 mg/kg). The median neurotoxic dose in mice is 332 mg/kg. After oral administration to rats, valrocemide is active in the MES test, with an ED 50 of 73 mg/kg, and the median neurotoxic dose is 1,000 mg/kg. Intraperitoneal administration of 300 mg/kg of valrocemide to hippocampal kindled Sprague–Dawley rats block generalized seizures and shorten the afterdischarge duration significantly. Valrocemide also provides complete protection from focal seizures in the corneally kindled rats (ED 50 , 161 mg/kg).